Table 1.
Characteristics of study population, by HIV/HCV strata.
|
HIV−/HCV−
(N=66) N (%) |
HIV+/HCV−
(N=66) N (%) |
HIV−/HCV+
(N=66) N (%) |
HIV+/HCV+
(N=66) N (%) |
|
|---|---|---|---|---|
| Age (median, IQR) | 44 (40–48) | 45 (41–49) | 47 (43–51) | 47 (43–52) |
| Race/ethnicity | ||||
| Black | 41 (62) | 41 (62) | 41 (62) | 41 (62) |
| Hispanic | 17 (26) | 17 (26) | 17 (26) | 17 (26) |
| Other | 8 (12) | 8 (12) | 8 (12) | 8 (12) |
| Current smoker | 50 (76) | 50 (76) | 50 (76) | 50 (76) |
| Body mass index (mean, SD) | 29.9 (6.5) | 28.4 (6.8) | 32.0 (8.9) | 26.8 (6.0) |
| C-reactive protein level (μg/mL) (median, IQR) | 3.2 (1.1–6.8) | 2.8 (1.2–5.6) | 1.5 (0.4–4.3) | 0.85 (0.3–2.45) |
| CD4+ count (cells/μL) (median, IQR) | N/A | 410 (248–599) | N/A | 392 (215–538) |
| HIV viral load (copies/mL) (median, IQR) | N/A | 885 (80–21000) | N/A | 98.5 (80–2200) |
| ART regimen at time of study | ||||
| Protease inhibitor-based | N/A | 26 (39) | N/A | 33 (50) |
| Non-protease inhibitor-based | N/A | 21 (32) | N/A | 22 (33) |
| Not on treatment | N/A | 19 (29) | N/A | 11 (17) |
| Inflammatory macrophage score (range: 0–3) | ||||
| 0 | 21 (32) | 15 (23) | 8 (12) | 4 (6) |
| 1 | 35 (53) | 24 (36) | 11 (17) | 9 (14) |
| 2 | 8 (12) | 14 (21) | 28 (42) | 21 (32) |
| 3 | 2 (3) | 13 (20) | 19 (29) | 32 (48) |
| Gal-3BP (μg/mL) (mean, SD) (range: 1.36–26.90) | 8.75 (5.61) | 8.43 (4.56) | 12.69 (5.99) | 12.14 (5.98) |
| sCD163 (ng/mL, log2-transformed) (mean, SD) (range: 8.23–13.83) | 10.07 (0.62) | 10.43 (0.79) | 11.13 (0.75) | 11.25 (0.75) |
| sCD14 (ng/mL) (mean, SD) (range: 439–3360) | 1,179 (287) | 1,477 (464) | 1,317 (330) | 1,649 (560) |
HCV = hepatitis C virus, HIV = human immunodeficiency virus, IQR = interquartile range, SD = standard deviation.